UBT251 — Safety, Research, Risks & Legal Status

Not medical advice. UBT251 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	UBT-251; GLP-1/GIP/glucagon triple agonist (United Bio-Technology)
Category	GLP-1 / Metabolic
Drug class	Synthetic peptide triple receptor agonist (GLP-1 / GIP / glucagon)
Developer	United Bio-Technology (Hengqin) Co., Ltd.; global ex-Greater China rights licensed to Novo Nordisk (March 2025, ~$2B deal)
Highest reported weight loss (Phase 2, 24 wk)	~19.7% mean body weight reduction vs. ~2.0% placebo (Chinese overweight/obesity cohort, n=205)
HbA1c reduction (Phase 2, T2D, 24 wk)	~2.16% mean reduction vs. placebo and semaglutide 1 mg (Chinese T2D cohort)
Current development stage	Phase 2 data published (China); global Phase 1b/2a underway via Novo Nordisk; topline global data expected 2027
Regulatory status	Class 1 innovative drug (China); approved for US clinical trials in T2D, obesity, CKD; not FDA-approved
US legal status	Unapproved investigational drug in the United States. Not approved by the FDA for any indication. Not available for human use outside of authorized clinical trials. Approved in China as a Class 1 innovative drug for type 2 diabetes, obesity, MAFLD, and chronic kidney disease (as of available data); China approval status may evolve as trials progress. Not a supplement; not for human consumption outside clinical trial settings.

What is UBT251?

UBT251 is a long-acting synthetic peptide under clinical development that simultaneously agonizes three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. It is intended as a once-weekly injectable for the treatment of obesity, type 2 diabetes, metabolic-associated fatty liver disease (MAFLD), and chronic kidney disease. Originally developed by United Bio-Technology (Hengqin) Co., Ltd. (a subsidiary of The United Laboratories International Holdings Limited), worldwide rights outside of Greater China were licensed exclusively to Novo Nordisk in March 2025 in a deal valued at approximately $2 billion. As of mid-2026, the compound has completed Phase 1b trials in China and published Phase 2 data; a global Phase 1b/2a trial initiated by Novo Nordisk is underway with topline results anticipated in 2027.

How it works

UBT251 is a triple incretin receptor agonist. It activates the GLP-1 receptor (reducing appetite, slowing gastric emptying, and stimulating glucose-dependent insulin secretion), the GIP receptor (augmenting insulin secretion and potentially modulating adipose tissue metabolism), and the glucagon receptor (which, counterintuitively, at low background insulin levels promotes energy expenditure and hepatic fat mobilization). The coordinated activation of all three pathways is hypothesized to produce additive or synergistic effects on weight reduction and glycemic control beyond what dual agonists (such as tirzepatide) achieve. Preclinical data reportedly demonstrated potent activity across all three receptors; human pharmacodynamic characterization is ongoing in Phase 1b/2 settings.

Background & history

UBT251 was developed by United Bio-Technology (Hengqin) Co., Ltd., a subsidiary of The United Laboratories International Holdings Limited, a Hong Kong-listed Chinese biotech. Phase 1b trials were conducted in China and completed ahead of a Phase 2 program. Phase 2 data in both an obesity/overweight population and a type 2 diabetes cohort were published in 2026. In March 2025, Novo Nordisk signed an exclusive worldwide licensing agreement (excluding Greater China) for UBT251, with the deal valued at approximately $2 billion, reflecting competitive interest in the triple agonist class. Novo Nordisk initiated its own global Phase 1b/2a trial, with topline data expected in 2027. The compound received Class 1 innovative drug designation in China and has been approved for US clinical trials in type 2 diabetes, obesity, and chronic kidney disease.

What the research says

Available human clinical data comes from Phase 1b and Phase 2 trials conducted in China. In the Phase 1b trial (36 patients), the highest dose group (1/3/6 mg titration) achieved approximately 15.1% mean weight loss at 24 weeks compared to a 1.5% weight increase in the placebo group. A Phase 2 trial in 205 Chinese patients with overweight or obesity (BMI ≥24) reported approximately 19.7% mean weight loss (equivalent to roughly 17.5 kg) versus approximately 2.0% in the placebo arm at 24 weeks. A separate Phase 2 cohort in patients with type 2 diabetes reported a 2.16% mean HbA1c reduction and approximately 9.8% weight loss relative to placebo and versus semaglutide 1 mg at 24 weeks. These results position UBT251 among the more numerically impressive candidates in the triple agonist space, though direct head-to-head trials against approved agents in diverse global populations have not been completed. All efficacy data published to date originate from Chinese patient populations under single-country trial conditions. Global Phase 1b/2a data from Novo Nordisk's program are pending (2027). Long-term safety, durability of weight loss, cardiovascular outcomes, and efficacy in non-Asian populations remain to be established.

Reported effects

Weight reduction: Phase 2 data show up to approximately 19.7% mean body weight loss at 24 weeks in overweight/obese patients (Chinese cohort)
Glycemic improvement: approximately 2.16% mean HbA1c reduction at 24 weeks in type 2 diabetes cohort
Weight loss in type 2 diabetes: approximately 9.8% body weight reduction in the T2D cohort
Appetite suppression: consistent with GLP-1 receptor agonism class effects
Potential hepatic fat reduction: glucagon receptor agonism is theorized to promote hepatic fat mobilization; formal MAFLD-specific endpoints are under investigation
Investigational activity in chronic kidney disease: trials ongoing; no published efficacy data in CKD available at time of writing

Dosing & administration (informational)

Phase 1b/2 trials in China tested dose-escalation regimens including a 1 mg / 3 mg / 6 mg titration schedule administered subcutaneously on a weekly basis. These are investigational protocol doses reported in the scientific literature for informational reference only. They do not constitute prescribing guidance, a treatment protocol, or a recommendation. Dosing for any GLP-1 class agent, including investigational compounds, must be determined by a licensed clinician within an appropriate clinical setting.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Gastrointestinal adverse events (nausea, vomiting, constipation, diarrhea) are the predominant reported side effects, consistent with the GLP-1 agonist drug class
Reported GI events in Phase 1b/2 were described as mostly mild-to-moderate in severity and diminishing over the course of treatment
No major unexpected safety signals reported in available Phase 1b/2 data; however, the dataset is small and follow-up is short (24 weeks)
Long-term safety profile (beyond 24 weeks) has not been established in published human data
Risk of hypoglycemia is theoretically modulated by the glucose-dependent mechanisms of GLP-1 and GIP agonism, but glucagon receptor agonism adds complexity; formal characterization is ongoing
Cardiovascular outcomes data do not exist for this compound; the approved incretin class agents carry their own cardiovascular study requirements that UBT251 has not yet completed
Not appropriate for self-administration; available only within authorized clinical trial protocols

Drug & supplement interactions

D
r
u
g
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
f
o
r
U
B
T
2
5
1
i
n
h
u
m
a
n
s
a
r
e
n
o
t
p
u
b
l
i
s
h
e
d
.
B
a
s
e
d
o
n
m
e
c
h
a
n
i
s
m
,
i
n
t
e
r
a
c
t
i
o
n
s
c
o
n
s
i
s
t
e
n
t
w
i
t
h
t
h
e
b
r
o
a
d
e
r
G
L
P
-
1
a
g
o
n
i
s
t
c
l
a
s
s
s
h
o
u
l
d
b
e
a
n
t
i
c
i
p
a
t
e
d
:
s
l
o
w
e
d
g
a
s
t
r
i
c
e
m
p
t
y
i
n
g
m
a
y
a
l
t
e
r
t
h
e
a
b
s
o
r
p
t
i
o
n
k
i
n
e
t
i
c
s
o
f
o
r
a
l
l
y
a
d
m
i
n
i
s
t
e
r
e
d
d
r
u
g
s
;
c
o
n
c
u
r
r
e
n
t
u
s
e
w
i
t
h
i
n
s
u
l
i
n
o
r
i
n
s
u
l
i
n
s
e
c
r
e
t
a
g
o
g
u
e
s
m
a
y
i
n
c
r
e
a
s
e
h
y
p
o
g
l
y
c
e
m
i
a
r
i
s
k
;
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
a
n
t
i
c
o
a
g
u
l
a
n
t
s
,
o
r
a
l
c
o
n
t
r
a
c
e
p
t
i
v
e
s
,
a
n
d
n
a
r
r
o
w
-
t
h
e
r
a
p
e
u
t
i
c
-
i
n
d
e
x
d
r
u
g
s
m
a
y
b
e
r
e
l
e
v
a
n
t
b
u
t
h
a
v
e
n
o
t
b
e
e
n
c
h
a
r
a
c
t
e
r
i
z
e
d
f
o
r
t
h
i
s
s
p
e
c
i
f
i
c
c
o
m
p
o
u
n
d
.
N
o
f
o
r
m
a
l
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
a
r
e
p
u
b
l
i
c
l
y
a
v
a
i
l
a
b
l
e
.

Who should avoid it

Use outside of authorized clinical trials - not approved for human consumption in the US
Sourcing from any unregulated vendor - no legitimate commercial supply exists
Use in pregnancy or lactation - no safety data
Self-administration without medical supervision
Combination with other weight loss agents or GLP-1 agonists outside a supervised trial setting

How it is commonly combined

No stacking data exist for UBT251. Combining investigational triple receptor agonists with other GLP-1 agents, weight loss drugs, or metabolic pharmaceuticals outside a clinical protocol is medically unsupported and carries unknown risk. The compound is not available outside clinical trials, making informal combination use a non-applicable and unsafe concept.

Legal & regulatory. Unapproved investigational drug in the United States. Not approved by the FDA for any indication. Not available for human use outside of authorized clinical trials. Approved in China as a Class 1 innovative drug for type 2 diabetes, obesity, MAFLD, and chronic kidney disease (as of available data); China approval status may evolve as trials progress. Not a supplement; not for human consumption outside clinical trial settings.

Quality & harm reduction

Safer, legal alternative we recommend

Liver Let Live. For liver and metabolic support, our Liver Support formula is a legal supplement option covering a similar goal.

See our recommended pick

Find UBT251 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What makes UBT251 different from tirzepatide (Mounjaro/Zepbound)?

Tirzepatide is a dual GLP-1/GIP agonist (approved). UBT251 adds a third target - the glucagon receptor - which is hypothesized to further enhance energy expenditure and hepatic fat clearance. Whether this translates into meaningfully superior clinical outcomes over tirzepatide in head-to-head trials has not been established; the available data are from different trial populations and designs and cannot be directly compared.

Is the ~19.7% weight loss result reliable?

The figure comes from a Phase 2 trial of 205 Chinese patients at 24 weeks. It is a credible early-phase result from a registered trial with published data, but it should be interpreted with appropriate caution: the population is Chinese (mean BMI ~28-29, lower than typical Western obesity trials), the trial is short-term, and global replication in larger, more diverse populations has not yet occurred. Phase 2 results frequently do not fully reproduce in Phase 3.

Can I participate in a UBT251 clinical trial?

Enrollment in clinical trials can be searched at ClinicalTrials.gov using the term 'UBT251.' Novo Nordisk is conducting a global Phase 1b/2a program. Eligibility criteria, locations, and open enrollment status must be confirmed through the trial registries or a clinician.

What is the recommended dose of UBT251?

There is no approved or recommended dose. Dose ranges tested in Phase 1b/2 trials (1/3/6 mg weekly escalation) are informational context from the scientific literature only. Determining any dose for clinical or experimental use requires a licensed clinician and an appropriate trial or medical setting. This reference does not provide dosing guidance.

Is UBT251 available to buy?

No. UBT251 is an unapproved investigational compound with no authorized commercial supply. Any vendor claiming to sell it is selling an unverified, unregulated substance with unknown identity and purity. Such products carry serious health risks and are not legal for human use in the United States.

How does the glucagon receptor component work in a weight-loss drug, given that glucagon raises blood sugar?

This is a key mechanistic question in the triple agonist class. Glucagon receptor agonism does raise hepatic glucose output in isolation, but when co-administered with GLP-1 and GIP agonism (which stimulate insulin secretion in a glucose-dependent manner), the net glycemic effect is largely offset. The intended benefit of glucagon co-agonism is increased energy expenditure and hepatic fat mobilization (relevant for MAFLD), not glycemic elevation. Balancing these effects requires careful dose optimization; the net metabolic impact in humans is still being characterized in ongoing trials.

References & further reading

PubMed: UBT251 GLP-1 GIP glucagon triple receptor agonist phase 2 obesity weight loss
PubMed: triple incretin agonist obesity type 2 diabetes clinical trial China
ClinicalTrials.gov: UBT251 obesity type 2 diabetes chronic kidney disease
PubMed: tirzepatide retatrutide triple agonist incretin obesity comparative efficacy
PubMed: GLP-1 GIP glucagon receptor co-agonism mechanism weight reduction